Non-Invasive Assessment of Liver Fibrosis and Disease Progression

Chronic liver disease poses a growing global health burden, driven in large part by metabolic risk factors and viral hepatitis. Fibrosis stage is the principal determinant of prognosis, yet liver biopsy remains invasive and subject to sampling error. Over the past decade, a range of blood-based panels, serum indices and imaging techniques has emerged to stage fibrosis and monitor progression without tissue sampling. Simple algorithms such as the fibrosis-4 index (FIB-4) and NAFLD fibrosis score combine routine biochemistry with demographic parameters to stratify risk. More sophisticated biomarkers measure extracellular matrix turnover or collagen neo-epitopes, while multiparametric elastography platforms quantify tissue stiffness and fat content. Sequential or combined strategies—using a low-cost serum test first, followed by imaging in indeterminate cases—optimise referral pathways and conserve resources. These tools now underpin screening algorithms in primary care, guide entry criteria for clinical trials in non-alcoholic steatohepatitis (NASH) and inform longitudinal risk prediction for cirrhosis complications and hepatocellular carcinoma. Continued refinement of biomarkers and incorporation of artificial-intelligence-driven image analysis promise further improvements in accuracy and accessibility.

Research from Nature Portfolio

A recent study evaluated five blood-based panels in a large cohort spanning the full spectrum of non-alcoholic fatty liver disease. Each panel was developed to identify either at-risk NASH (a combination of steatohepatitis, histological activity and fibrosis ≥ stage 2) or discrete fibrosis stages up to cirrhosis. In over a thousand participants, composite scores incorporating proteomic markers, collagen-derived fragments and clinical biochemistry all achieved area under the receiver operating characteristic curves ≥0.8 for their intended endpoints. Notably, certain panels outperformed routine transaminase measurements and the FIB-4 index for detecting clinically significant and advanced fibrosis. These data mark a milestone towards regulatory qualification of multiple non-invasive biomarkers for both disease activity and fibrosis severity in metabolic liver disease.

Non-Invasive Assessment of Liver Fibrosis and Disease Progression publication trend

The graph below shows the total number of articles in non-invasive assessment of liver fibrosis and disease progression across all publications each year (not limited to Nature Index journals).

Technical terms

Fibrosis-4 index (FIB-4): An algorithm combining age, transaminase levels and platelet count to estimate liver fibrosis.

Enhanced liver fibrosis (ELF) test: A panel measuring serum markers of matrix turnover to stage fibrosis non-invasively.

Vibration-controlled transient elastography (VCTE): An ultrasound-based method that quantifies liver stiffness as a surrogate for fibrosis.

Area under the receiver operating characteristic curve (AUROC): A measure of test accuracy, with higher values indicating better discrimination between disease stages.

Non-alcoholic steatohepatitis (NASH): An aggressive form of fatty liver disease characterised by inflammation, hepatocyte injury and variable fibrosis.

Sequential testing strategy: An approach that applies a simple, low-cost test first, followed by a second, more specific test only in indeterminate cases to optimise resource use.

References

1. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nature Medicine (2023).
2. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. The Lancet Gastroenterology & Hepatology (2023).
3. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. Journal of Hepatology (2023).